Evidence map›Paper›PMID 41786623›Full record

ArticleHead & neck2026

Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16- Patients Affected by Oropharyngeal Carcinoma.

Riccardo Gili, Paolo Bossi, Luca Lalli, Lisa Francesca Linda Licitra, Marta Maddalo, Almalina Bacigalupo, Liliana Belgioia, Jon Cacicedo, Nadia Facchinetti, Almudena Garcia Castano and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Riccardo GiliMedical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Paolo BossiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Luca LalliUnit of Translational Immunology, IRCCS Foundation National Cancer Institute, Milan, Italy.
Lisa Francesca Linda LicitraFondazione IRCCS Istituto Nazionale dei Tumori and, University of Milan, Milan, Italy.
Marta MaddaloRadiation Oncology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.
Almalina BacigalupoRadiation Oncology Policlinico San Martino IRCCS, Genoa, Italy.
Liliana BelgioiaRadiation Oncology Policlinico San Martino IRCCS, Genoa, Italy.
Jon CacicedoDepartment of Radiotherapy, Cruces University Hospital. Osakidetza, Basque Health Service, Barakaldo, Spain.
Nadia FacchinettiRadiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Almudena Garcia CastanoMedical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Marc OlivaInstitut Català d'Oncologia L'Hospitalet, Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Italy.
Pierluigi BonomoRadiation Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Giuseppe SanguinetiDepartment of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Pierfrancesco FrancoDepartment of Radiation Oncology, 'Maggiore della Carità' University Hospital, Novara, Italy.
Athanassios ArgirisSidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Amanda PsyrriSection of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
Ester OrlandiDepartment of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOropharyngeal cancer (OPC) exhibits distinct clinical behaviors according to HPV/p16 status and smoking exposure. While HPV-positive OPC generally shows superior survival, differences in recurrence patterns remain unclear.

methodsA retrospective multicenter analysis of 674 AJCC VII edition Stage III-IVa/b OPC patients treated with definitive IMRT ± systemic therapy was conducted across 14 Southern European centers. Recurrence patterns, disease-free survival (DFS), overall survival (OS), and survival after recurrence (rOS) were compared between p16 groups and across smoking categories.

resultsHPV-positive tumors showed a higher incidence of distant recurrence, particularly among heavy smokers, while p16-negative OPC displayed predominantly locoregional failure. p16-positive patients had significantly better DFS, OS, and rOS.

conclusionRecurrence patterns in OPC differ by HPV status and smoking history. HPV-positive heavy smokers represent a distinct high-risk subgroup characterized by increased distant metastasis and inferior survival, warranting refined stratification beyond p16 status alone.

Indexed as

Carcinoma, Squamous CellChemoradiotherapyNeoplasm Recurrence, LocalOropharyngeal NeoplasmsAgedCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalEuropeFemaleHuman Papillomavirus VirusesHumansMaleMiddle AgedNeoplasm StagingPapillomavirus InfectionsRetrospective StudiesCyclin-Dependent Kinase Inhibitor p16chemoradiotherapy outcomesHPV/p16 statusoropharyngeal squamous cell carcinomarecurrence patternssmoking history

Identifiers

PMID41786623
PMCPMC13332578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.